Signal Advisors Wealth LLC lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 58.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,981 shares of the biopharmaceutical company’s stock after selling 17,177 shares during the period. Signal Advisors Wealth LLC’s holdings in Bristol Myers Squibb were worth $540,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Summit Financial LLC raised its position in Bristol Myers Squibb by 32.7% during the first quarter. Summit Financial LLC now owns 18,881 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 4,648 shares in the last quarter. Compound Planning Inc. lifted its stake in Bristol Myers Squibb by 9.8% during the first quarter. Compound Planning Inc. now owns 14,023 shares of the biopharmaceutical company’s stock worth $855,000 after purchasing an additional 1,255 shares during the last quarter. Sax Wealth Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 5.1% in the 1st quarter. Sax Wealth Advisors LLC now owns 6,343 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 307 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Bristol Myers Squibb by 3.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 22,689 shares of the biopharmaceutical company’s stock valued at $1,362,000 after purchasing an additional 752 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
- Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
- Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
- Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
- Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
- Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
- Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
- Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company’s dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Bristol Myers Squibb
Bristol Myers Squibb Trading Up 1.5%
NYSE:BMY opened at $54.15 on Monday. The firm has a market capitalization of $110.24 billion, a P/E ratio of 18.29, a P/E/G ratio of 8.29 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The company has a fifty day moving average of $47.73 and a 200 day moving average of $47.14. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.
Bristol Myers Squibb Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date of this dividend is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
See Also
- Five stocks we like better than Bristol Myers Squibb
- I Shouldn’t Be Sending You This
- Wall Street Stock picker Names #1 Stock of 2026
- End of America update
- They Laughed at $30. They Won’t Laugh at $70.
- How Long Will $1M Last in Retirement?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
